<DOC>
	<DOCNO>NCT02008877</DOCNO>
	<brief_summary>Phase 1 : To assess safety , tolerability , maximum tolerate dose ( MTD ) / recommend dose ganetespib administer combination sirolimus patient refractory relapse sarcoma include unresectable metastatic sporadic neurofibromatosis type 1 ( NF1 ) associate MPNST . Phase I enrollment closed . Phase 2 : To determine clinical benefit ganetespib combination sirolimus patient unresectable metastatic sporadic NF1 associate MPNST .</brief_summary>
	<brief_title>SARC023 : Ganetespib Sirolimos Patients With MPNST ( Malignant Peripheral Nerve Sheath Tumors )</brief_title>
	<detailed_description>Previously , target agent able cause tumor regression genetically engineer MPNST mouse model human MPNST . Recently publish data Dr. Cichowski 's laboratory demonstrate use Hsp90 inhibitor enhance endoplasmic reticulum stress couple mammalian target rapamycin ( mTOR ) inhibitor sirolimus lead dramatic tumor shrinkage transgenic MPNST mouse model , correlate profound damage endoplasmic reticulum cell death . Ganetespib novel , injectable , small molecule inhibitor Hsp90 currently investigate adult broad range tumor type favorable safety profile promise early result . Ganetespib study preclinical vivo model variety target agent marked apparent pharmacological interaction . Sirolimus commercially available orally administer mTOR inhibitor active metabolite temsirolimus , FDA approve agent advance metastatic renal cell carcinoma . Sirolimus study tolerate combination multiple cytotoxic target agent variety tumor type . Based strong preclinical rationale , investigator hypothesize ganetespib combination sirolimus cause tumor regression patient refractory MPNSTs . The investigator propose multi-institutional open label phase I/II trial ganetespib combination sirolimus patient refractory sarcoma include MPNST . Hsp90 inhibitor mTOR inhibitor also demonstrate benefit variety preclinical bone soft tissue sarcoma model . The investigator hypothesize agent work separate potentially synergistic pathway also beneficial refractory bone soft tissue sarcoma . Thus , phase I component open patient refractory sarcoma , also expedite enrollment . Upon determination recommend dosing , phase II study conduct . The phase II study population limit patient diagnosis MPNST .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurilemmoma</mesh_term>
	<mesh_term>Neurofibrosarcoma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients â‰¥ 16 year old Patients unresectable metastatic histologically confirm sporadic NF1 associate high grade MPNST Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Patients must least 1 measurable tumor Patients must fully recover acute toxic effect prior anticancer therapy ( toxicity &lt; grade 2 ) Must able swallow whole pill Adequate organ function Normal fast cholesterol triglyceride May cholesterol medication Patients receive current treatment corticosteroid another immunosuppressive . Topical inhale corticosteroid allow . Uncontrolled brain leptomeningeal metastasis , include patient continue require glucocorticoid brain leptomeningeal metastases Symptomatic congestive heart failure Severely impaired lung function Significant vascular disease Uncontrolled diabetes Active ( acute chronic ) uncontrolled severe infection hepatitis Impairment gastrointestinal function Patients active , bleed diathesis significant coagulopathy Use cytochrome P450 isoenzyme 3A4 ( CYP3A4 ) / CYP2C19 substrate</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Malignant Peripheral Nerve Sheath Tumors</keyword>
	<keyword>MPNST</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Ganetespib</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>mTOR inhibitor</keyword>
	<keyword>Heat shock protein</keyword>
	<keyword>Hsp90</keyword>
</DOC>